Overview

Tucatinib is a HER2-selective, reversible tyrosine kinase inhibitor distinguished by its selectivity for HER2 over EGFR, which limits certain off-target toxicities. It is used together with trastuzumab and capecitabine in HER2-positive metastatic breast cancer, including cases with brain metastases. The 150 mg tablet offers a CNS-penetrant option that distributors value for its differentiated mechanism among anti-HER2 agents and for the oral convenience it brings to a historically infusion-heavy treatment area. Oral administration keeps most of the regimen outpatient-based, reserving infusion capacity for the trastuzumab component rather than the kinase inhibitor.

How It Works

Tucatinib binds the intracellular kinase domain of HER2 and blocks downstream PI3K–AKT and MAPK signaling that drives proliferation and survival. Its EGFR-sparing profile reduces diarrhea compared with broader pan-HER inhibitors. Clinically meaningful central-nervous-system penetration allows activity against leptomeningeal and parenchymal brain lesions that larger antibodies reach poorly, which is why it is frequently chosen when intracranial disease is a concern in HER2-positive metastatic breast cancer. Selective HER2 blockade spares the epidermal growth factor receptor that pan-HER agents hit, which is the main reason gastrointestinal tolerability is comparatively favorable.

Indications

The approved use is HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, including patients with stable brain metastases. Selection follows confirmed HER2-positive status by assay, and the triple combination has become a reference option in later lines where brain involvement limits antibody-only approaches. Its role is strongest where central nervous system disease limits antibody reach, making it a reference choice for metastatic programs with intracranial involvement.

Dosage & Administration

The regimen pairs tucatinib 300 mg twice daily with trastuzumab and capecitabine, assembled from 150 mg tablets, continuing until progression or unacceptable toxicity, with hepatic monitoring because dose adjustment is required in liver impairment.

Storage & Sourcing

Tablets are packed in desiccant-protected blisters with cold-chain-compatible cartons. GIVE LIFE TIME International provides lot-traceable supply and export compliance documents for international partners.

FAQ

Q: Why is tucatinib HER2-selective? A: Its preference for HER2 over EGFR reduces EGFR-related diarrhea while still blocking HER2 signaling.

Q: Does it help brain metastases? A: Yes, tucatinib penetrates the CNS, supporting control of HER2-positive brain lesions in metastatic breast cancer.

Q: How is it combined in practice? A: It is given with trastuzumab and capecitabine as a triple oral-plus-infusion regimen.